{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T17:01:56Z","timestamp":1780678916185,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bcp.2026.117982","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:22:53Z","timestamp":1776284573000},"page":"117982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Ailanthone targets the EGR3-SOCS2 regulatory pathway to suppress vasculogenic mimicry in prostate cancer"],"prefix":"10.1016","volume":"250","author":[{"given":"Hong","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanming","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bcp.2026.117982_b0005","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","article-title":"Epidemiology and prevention of prostate cancer","volume":"4","author":"Gandaglia","year":"2021","journal-title":"Eur. Urol. Oncol."},{"issue":"16","key":"10.1016\/j.bcp.2026.117982_b0010","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate cancer: a review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2026.117982_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27175730","article-title":"Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches","volume":"27","author":"Sekhoacha","year":"2022","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.bcp.2026.117982_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy"},{"issue":"1","key":"10.1016\/j.bcp.2026.117982_b0025","first-page":"101","article-title":"Targeting treatment options for castration-resistant prostate cancer","volume":"9","author":"Miller","year":"2021","journal-title":"Am. J. Clin. Exp. Urol."},{"issue":"22","key":"10.1016\/j.bcp.2026.117982_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214257","article-title":"Complexities of prostate cancer","volume":"23","author":"Wasim","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.117982_b0035","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2022.01.015","article-title":"Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer","volume":"530","author":"Kang","year":"2022","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.bcp.2026.117982_b0040","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/s41417-022-00454-5","article-title":"TMPRSS2-ERG promotes the initiation of prostate cancer by suppressing oncogene-induced senescence","volume":"29","author":"Fang","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.117982_b0045","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.bcp.2026.117982_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112791","article-title":"FOXC2 promotes vasculogenic mimicry and resistance to anti-angiogenic therapy","volume":"42","author":"Cannell","year":"2023","journal-title":"Cell Rep."},{"issue":"9","key":"10.1016\/j.bcp.2026.117982_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092382","article-title":"Angiogenesis inhibition in prostate cancer: an update","volume":"12","author":"Sarkar","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2026.117982_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107805","article-title":"Vasculogenic mimicry, a complex and devious process favoring tumorigenesis - interest in making it a therapeutic target","volume":"223","author":"Treps","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2026.117982_b0065","doi-asserted-by":"crossref","first-page":"62","DOI":"10.17116\/patol20238506162","article-title":"Vasculogenic mimicry","volume":"85","author":"Lapkina","year":"2023","journal-title":"Arkh. Patol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117982_b0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-020-01288-1","article-title":"Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments","volume":"20","author":"Wei","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2026.117982_b0075","article-title":"Molecular vasculogenic mimicry-related signatures predict clinical outcomes and therapeutic responses in bladder cancer: results from real-world cohorts","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117982_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1206141","article-title":"Vasculogenic mimicry score identifies the prognosis and immune landscape of lung adenocarcinoma","volume":"14","author":"Yang","year":"2023","journal-title":"Front. Genet."},{"issue":"3","key":"10.1016\/j.bcp.2026.117982_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031321","article-title":"Sp1 plays a key role in vasculogenic mimicry of human prostate cancer cells","volume":"23","author":"Han","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.117982_b0090","doi-asserted-by":"crossref","first-page":"436","DOI":"10.7150\/thno.90322","article-title":"Vitamin D binding protein (VDBP) hijacks twist1 to inhibit vasculogenic mimicry in hepatocellular carcinoma","volume":"14","author":"Qin","year":"2024","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.bcp.2026.117982_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/cells10071758","article-title":"Vasculogenic mimicry in breast cancer: clinical relevance and drivers","volume":"10","author":"Morales-Guadarrama","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2026.117982_b0100","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27238367","article-title":"Natural products as anticancer agents: current status and future perspectives","volume":"27","author":"Naeem","year":"2022","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.bcp.2026.117982_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.972345","article-title":"Research advance of natural products in tumor immunotherapy","volume":"13","author":"Huo","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117982_b0110","doi-asserted-by":"crossref","first-page":"774","DOI":"10.20892\/j.issn.2095-3941.2022.0006","article-title":"Anti-tumor pharmacology of natural products targeting mitosis","volume":"19","author":"Huang","year":"2022","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.bcp.2026.117982_b0115","article-title":"Breaking the bottlenecks in anti-tumor angiogenic therapy: targeting vasculogenic mimicry with natural products and traditional Chinese medicine","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"14","key":"10.1016\/j.bcp.2026.117982_b0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23147659","article-title":"Endothelium-dependent induction of vasculogenic mimicry in human triple-negative breast cancer cells is inhibited by calcitriol and curcumin","volume":"23","author":"Morales-Guadarrama","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2026.117982_b0125","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s12079-022-00693-z","article-title":"Lupeol and Paclitaxel cooperate in hindering hypoxia induced vasculogenic mimicry via suppression of HIF-1\u03b1-EphA2-Laminin-5\u03b32 network in human oral cancer","volume":"17","author":"Saha","year":"2023","journal-title":"J. Cell Commun. Signaling"},{"issue":"2","key":"10.1016\/j.bcp.2026.117982_b0130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11655-017-2410-3","article-title":"Gambogic acid induces cell apoptosis and inhibits MAPK pathway in PTEN(-\/-)\/p53(-\/-) prostate cancer cells in vitro and ex vivo","volume":"24","author":"Pan","year":"2018","journal-title":"Chin. J. Integr. Med."},{"issue":"44","key":"10.1016\/j.bcp.2026.117982_b0135","doi-asserted-by":"crossref","first-page":"77181","DOI":"10.18632\/oncotarget.20424","article-title":"Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer","volume":"8","author":"Pan","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.bcp.2026.117982_b0140","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/ptr.6681","article-title":"Anticancer properties and mechanism of action of the quassinoid ailanthone","volume":"34","author":"Bailly","year":"2020","journal-title":"Phytother. Res. PTR"},{"key":"10.1016\/j.bcp.2026.117982_b0145","article-title":"Ailanthone increases cisplatin-induced apoptosis and autophagy in cisplatin resistance non-small cell lung cancer cells through the PI3K\/AKT\/mTOR pathway","author":"Di","year":"2024","journal-title":"Curr. Med. Chem."},{"issue":"Pt B","key":"10.1016\/j.bcp.2026.117982_b0150","article-title":"Ailanthone: a multi-targeting Quassinoid from Ailanthus altissima for broad-spectrum cancer therapy - a comprehensive review of mechanisms, pharmacokinetics, and clinical prospects","volume":"355","author":"Huang","year":"2025","journal-title":"J. Ethnopharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117982_b0155","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18033","article-title":"Ailanthone synergizes with PARP1 inhibitor in tumour growth inhibition through crosstalk of DNA repair pathways in gastric cancer","volume":"28","author":"Wang","year":"2024","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.bcp.2026.117982_b0160","article-title":"The role played by ailanthone in inhibiting bone metastasis of breast cancer by regulating tumor-bone microenvironment through the RANKL-dependent pathway","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2026.117982_b0165","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3859489","article-title":"Ailanthone inhibits cell proliferation in tongue squamous cell carcinoma via PI3K\/AKT pathway","volume":"2022","author":"Wang","year":"2022","journal-title":"Evid. Based Complement. Alternat. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.117982_b0170","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2021.5076","article-title":"Ailanthone suppresses the activity of human colorectal cancer cells through the STAT3 signaling pathway","volume":"49","author":"Ding","year":"2022","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bcp.2026.117982_b0175","doi-asserted-by":"crossref","first-page":"16","DOI":"10.25259\/Cytojournal_166_2024","article-title":"Ailanthone inhibits bladder cancer tumor and cell proliferation, epithelial-mesenchymal transition, and activation of the Janus kinase\/signal transducer and activator of transcription 3 signaling pathway","volume":"22","author":"Li","year":"2025","journal-title":"CytoJournal"},{"issue":"16","key":"10.1016\/j.bcp.2026.117982_b0180","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.2174\/0929867329666220819093117","article-title":"Discovery of STAT3 inhibitors: recent advances and future perspectives","volume":"30","author":"Song","year":"2023","journal-title":"Curr. Med. Chem."},{"issue":"49","key":"10.1016\/j.bcp.2026.117982_b0185","doi-asserted-by":"crossref","first-page":"85997","DOI":"10.18632\/oncotarget.20844","article-title":"STAT3 and STAT5A are potential therapeutic targets in castration-resistant prostate cancer","volume":"8","author":"Mohanty","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.bcp.2026.117982_b0190","doi-asserted-by":"crossref","first-page":"e978","DOI":"10.1002\/ctm2.978","article-title":"The driver role of JAK-STAT signalling in cancer stemness capabilities leading to new therapeutic strategies for therapy- and castration-resistant prostate cancer","volume":"12","author":"Lo","year":"2022","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117982_b0195","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s12964-025-02298-6","article-title":"Evidence for a JAK2\/STAT3 proinflammatory and vasculogenic mimicry interrelated molecular signature in adipocyte-derived mesenchymal stromal\/stem cells","volume":"23","author":"Veilleux","year":"2025","journal-title":"Cell Commun. Signal"},{"issue":"18","key":"10.1016\/j.bcp.2026.117982_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810389","article-title":"Antheraea pernyi suppressor of cytokine signaling 2 negatively modulates the JAK\/STAT pathway to attenuate microbial infection","volume":"23","author":"Kausar","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"Pt 3","key":"10.1016\/j.bcp.2026.117982_b0205","article-title":"Oral RNAi delivery for targeting Ftz-F1\u03b2\/JAK-STAT signaling axis to boost shrimp immunity against pathogen infection","volume":"322","author":"Zuo","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117982_b0210","doi-asserted-by":"crossref","first-page":"7032","DOI":"10.1038\/s41467-021-26983-5","article-title":"Discovery of an exosite on the SOCS2-SH2 domain that enhances SH2 binding to phosphorylated ligands","volume":"12","author":"Linossi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.117982_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2022.148096","article-title":"Functional mechanism of EGR3 in cerebral ischemia\/reperfusion injury in rats by modulating transcription of pri-miR-146a\/146b to miR-146 and suppressing SORT1 expression","volume":"1797","author":"Han","year":"2022","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2026.117982_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.680441","article-title":"EGR3-HDAC6-IL-27 axis mediates allergic inflammation and is necessary for tumorigenic potential of cancer cells enhanced by allergic inflammation-promoted cellular interactions","volume":"12","author":"Kwon","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.117982_b0225","article-title":"Chemoproteomics reveals Ailanthone directly binds to PKM2 to inhibit the progression of Hepatocellular carcinoma","volume":"143","author":"Lin","year":"2025","journal-title":"Phytomed. Int. J. Phytother. Phytopharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117982_b0230","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13014-024-02480-z","article-title":"Transcriptomic response of prostate cancer cells to carbon ion and photon irradiation with focus on androgen receptor and TP53 signaling","volume":"19","author":"H\u00e4nze","year":"2024","journal-title":"Radiat. Oncol. (London England)"},{"key":"10.1016\/j.bcp.2026.117982_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2024.110988","article-title":"SOCS modulates JAK-STAT pathway as a novel target to mediate the occurrence of neuroinflammation: molecular details and treatment options","volume":"213","author":"Yan","year":"2024","journal-title":"Brain Res. Bull."},{"issue":"5","key":"10.1016\/j.bcp.2026.117982_b0240","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.tips.2019.03.001","article-title":"Targeting SOCS proteins to control JAK-STAT signalling in disease","volume":"40","author":"Durham","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2026.117982_b0245","article-title":"Ailanthone inhibits non-small cell lung cancer growth and metastasis through targeting UPF1\/GAS5\/ULK1 signaling pathway","volume":"128","author":"Fang","year":"2024","journal-title":"Phytomed. Int. J. Phytother. Phytopharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117982_b0250","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/s12935-024-03594-w","article-title":"Ailanthone disturbs cross-talk between cancer cells and tumor-associated macrophages via HIF1-\u03b1\/LINC01956\/FUS\/\u03b2-catenin signaling pathway in glioblastoma","volume":"24","author":"Deng","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bcp.2026.117982_b0255","article-title":"Elucidation of the mechanism of action of ailanthone in the treatment of colorectal cancer: integration of network pharmacology, bioinformatics analysis and experimental validation","volume":"15","author":"Ma","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"20","key":"10.1016\/j.bcp.2026.117982_b0260","doi-asserted-by":"crossref","first-page":"18103","DOI":"10.1007\/s00432-023-05503-6","article-title":"EGR3 and estrone are involved in the tamoxifen resistance and progression of breast cancer","volume":"149","author":"Xie","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2026.117982_b0265","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.70399","article-title":"EGR3 Transcriptionally Upregulates the expression of DCN in liver cancer to inhibit tumor progression","volume":"39","author":"Yang","year":"2025","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117982_b0270","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-020-00858-6","article-title":"Vasculogenic mimicry in carcinogenesis and clinical applications","volume":"13","author":"Luo","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.117982_b0275","article-title":"New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects","volume":"64","author":"Huang","year":"2022","journal-title":"Drug Resistance Updates Rev. Commentaries Antimicrob. Anticancer Chemother."},{"issue":"3","key":"10.1016\/j.bcp.2026.117982_b0280","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1002\/cam4.5110","article-title":"ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinoma","volume":"12","author":"Shi","year":"2023","journal-title":"Cancer Med."},{"issue":"8","key":"10.1016\/j.bcp.2026.117982_b0285","first-page":"3892","article-title":"Prrx1 promotes resistance to temozolomide by upregulating ABCC1 and inducing vasculogenic mimicry in glioma","volume":"12","author":"Chen","year":"2022","journal-title":"Am. J. Cancer Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226003151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226003151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:20:42Z","timestamp":1780676442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226003151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":57,"alternative-id":["S0006295226003151"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117982","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ailanthone targets the EGR3-SOCS2 regulatory pathway to suppress vasculogenic mimicry in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117982","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117982"}}